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( -)-[3H]Desmethoxyverapamil and ( +)-[3H]PN 200-I 10 were employed to characterize phenylalkylamine- 
selective and 1,4-dihydropyridine-selective r ceptors on purified Ca *+ channels from guinea-pig skeletal 
muscle t-tubules. In contrast to the membrane-bound Ca2+ channel, d-cis-diltiazem (EC,,=4.5f 1.7 PM) 
markedly stimulated the binding of (+)-[“H]PN 200-l 10 to the purified ionic pore. In the presence of 100 
PM d-cis-diltiazem (which binds to the benzothiazepine-selective receptors) the B,,, for ( +)j3H]PN 200-l 10 
increased from 497 + 81 to 1557 _I 43 pmol per mg protein, whereas the & decreased from 8.8 rfr 1.7 to 
4.7 i: 1.8 nM at 25°C. P-cis-Diltiazem was inactive. f -)-Desmethoxyverapamil, which is a negative hetero- 
tropic allosteric inhibitor of ( +)-[3H]lN 200-I 10 binding to membrane-bound channels, stimulated 1,4-di- 
hydropyridine binding to the isolated channel. ( -)-[3H]Desmethoxyverapamil binding was stimulated by 
antagonistic 1,Cdihydropyridines [( +)-PN 200-l lO> (-)(R)-202-791> (+)(4R)-Bay K 86441 whereas the 
agonistic enantiomers (-+-)(a-202-791 and (-)(4S)-Bay K 8644 were inhibitory and (-)-PN 200-l 10 was 
inactive. The results indicate that three distinct drug-receptor sites exist on the purified Ca*+ channel, two 
of which are shown by direct labelling to be reciprocally allosterically coupled. 
Caz+ channel (Skeletal muscle) Allosterism I,4-Dihydropyridine Phenylalkylamine 
1. INTRODUCTION 
Skeletal muscle Ca2+ channels, first labelled 
directly with the 1,Cdihydropyridine [3H]nimo- 
dipine [l], have been shown to be nearly exclusive- 
ly localized in t-tubule membranes [2,3]. As the 
density of these channels compared to, e.g. heart, 
brain or smooth muscle is high [4], they have 
become the most favoured for solubilization and 
purification of the channel proteins 15-81, photo- 
affinity labelling 19, lo], reconstitution [ 111 and 
detailed characterisation of distinct drug-receptor 
sites, including target size analysis 1121. There is 
strong evidence that the Ca’+ channel has 3 drug- 
receptor domains (one selective for 1,6dihydro- 
pyridines, one for phenylalkylamines and one for 
d-cj~-dilti~em) which are function~ly linked to 
* To whom correspondence should be addressed 
each other by reciprocal allosteric coupling 
mechanisms and to Ca2+-binding sites [13,14]. 
Binding of the phenylalkylamine verapamil to its 
site lowers the affinity of the 1,6dihydropyridine- 
selective site [l], whereas the potent 1 ,Cdihydro- 
pyridine (+)-PN 200-l 10 inhibits, via a similar 
allosteric mechanism, binding of the potent 
phenylalkylamine ( -)-[3H]desmethoxyverapamil 
to its receptor [15]. So far all of these studies have 
been performed with particulate or solubilized 
Ca2+ channels [4]. Here, we describe that the 
purified channel also shows reciprocal allosteric 
regulation between ( +)-[3H]PN 200-l IO-labelled 
1,4_dihydropyridine receptors and the (- )-[‘HI- 
desmethoxyverapamil-labelled phenylalkylamine 
site. In addition, we find that the purified prepara- 
tion has stereospecific sites for the diltiazem dia- 
stereoisomers, indicating that the 3 drug-receptor 
sites copurify. 
204 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/$3.50 0 1986 Federation of European Biochemical Societies 
Volume 197, number 1,2 FEBS LETTERS March 1986 
2. MATERIALS AND METHODS 
2.1. Mater&& 
( -)-[3H]Desmethoxyverapamil (83 Ci/mmol) 
and the unlabelled optically pure enantiomers of 
desmethox~erap~il were gifts from Knoll; (+)- 
[3H]PN 200-110 (binding ability > 85%; 75 Ci/ 
mmol) was from Amersham. The PN 200-l 10 
enantiomers, ( - )(R)- and ( -t- )(S)-202-791 [iso- 
propyl-4-(2,1,3 - benzoxadiazol-4-yl)- 1,4-dihydro- 
2,~-dimeth~l-5-nitro-3-p~idine carboxylate], were 
from Sandoz; the optically pure enantiomers 
( + ~~4~~-Bay K 8644 and { - )(4S)-Bay K 8644 and 
(~!~)-[~r-iJBay K 8644 (78 Ci/mmol) were from 
Bayer. Benzamidine and pepstatin A were from 
Sigma. 
purification 
Partially purified skeletal muscle t-tubule mem- 
branes from guinea-pig hind limbs were prepared 
as described in [l] and kept in liquid nitrogen for 
up to 1 month until1 use. The purification pro- 
cedure followed ~senti~ly the strategies outlined 
in [4,5] with the following modifications: 0.1 mM 
benzamidine, 1 .O mM iodoacetamide, 1fiM 
pepstatin A were present in all buffers and sucrose 
gradient centrifugation after affinity chromatog- 
raphy was performed in a Beckman VT I 50 rotor 
as described [7]. Purity of the channel was assessed 
by SDS-PAGE on 5-l 5% polyacrylamide gradient 
gels and silver staining [ 161, photoaffinity labelling 
[9,10] and post-labelling with ’ ( + )-[3H]PN 
200-l 10. With the latter method the specific activi- 
ty of the channel was ,) 1500 pmol per mg protein, 
which is equal to the calculated value of the chan- 
nel purified from rabbit skeletal muscle t-tubule 
membranes [‘7,8]. 
2.3, Binding assays 
The conditions for the birding assay with 
purified channels were essentially as in [4], except 
that all incubations were performed in a volume of 
0.25 ml for 60 min at 25°C. ( +-)-[3H]PN 200-l 10 
(for experiments to evaluate the effects of unla- 
belled drugs) was 2-3.5 nM. For saturation studies 
the free ligand concentration was varied between 
0.4 and 30 nM. The (- )-f3H]desmethox- 
yverapamil concentration was 6-10 nM; for 
saturation studies the free concentration was 
varied between 3 and 350 nM by decreasing the 
specific activity with unlabelled ( - )-desmethox- 
yverapamil. The non-specific binding for ( +)- 
[3H]PN 200-l 10 assays was defined using 3 pM 
( + )-PN 200-l 10 and 30 ,YM (-)-desmethox- 
yverapamif for ( - )-~3H]desmethoxyverapamil 
assays, respectively. Bound and free Iigand were 
separated after addition of carrier protein with the 
polyethylene glycol method [4]. For membrane- 
bound channels conditions were as described [4]. 
The non-specific binding for (&)-[3H]Eay K 8644 
and (+ )-13H]PN 200-110 experiments with par- 
ticulate membranes was defined using 1 gM PN 
200-I 10. Data are given as means +: SE for 3 in- 
dependent experiments except for binding inhibi- 
tion or stimulation data where the asymptotic 
standard deviation obtained by parameter fitting 
of pooled data with non-linear methods is 
presented [4,5]. ICSO and EC50 values indicate the 
drug concentration causing 50% inhibition or 50% 
stimulation, respectively. inhibition is defined as 
100 x (B&3)/3 where B is the specific binding of 
3H-labeiled ligand in the presence and Be in the 
absence of added drug. Stimulation is defined as 
100 x (B-iso)/&. 
3. RESULTS 
3.1. C~ar~~ter~s#ics of the ~,4-d~~yd~upyrid~ne 
receptors 
Previously is was shown that binding of [3H]- 
nifedipine > [3H]nimodipine = [3H]nitrendipine & 
[3H]PN2~~l10 to particulate calcium channels in 
skektal muscle was stimulated by d-cis-diltiazem at 
37*C, mainly by increasing the apparent density of 
receptors which were stabilised in the high-affinity 
state 1171. Fig.lA shows that the binding of (+)- 
[3H]PN 200-l 10 to purified channels is stimulated 
by d-cis-diitiazem in a concentration-dependent 
manner. The I& value (n = 3) was 4.5 ri: 1.7 PM, 
the maximum stimulation being 369 f 40%. 
Saturation analysis gave a & value for ( +)- 
[3H]PN 200-110 of 8.8 -+ 1.7 nM (n = 3) in the 
absence of d-cis-diltiazem whereas with 1OOpM d- 
cj~-diltiaz~m the dissociation constant decreased to 
4.7 f 1.8 n&f, A concomitant increase in Bnrax was 
observed (497 f 81 vs I557 f 43 pmol per mg pro- 
tein). An example is shown in fig.lB. The dia- 
stereoisomer I-cis-diltiazem, which is not a Ca2+- 
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Fig. 1. Equilibrium binding properties of the 1,4-dihydropyridine-selective r ceptor, labelled by ( +)-[3H]PN 200-I 10. 
(A) Stereospecific regulation of (+)-[-‘H]PN 200-l 10 binding by the diastereoisomers of diltiazem, and the enantiomers 
of PN 200-l 10 and desmethoxyverapamil ( nset). ( +)-[3H]PN 200-l 10 (2.0-3.5 nM) was incubated with 0.08-0.17 pg 
channel protein for 60 min at 25°C. BO is the specifically bound ligand in the absence, and B in the presence of unla- 
belled drug. Data were obtained from at least 2-3 independent experiments. ICSO (or ECse) values and apparent Hill 
slopes (au) are given f asymptotic SD. (0) (+)-PN 200-110 - ICse = 12.3 + 3.5 nM, nH = 1.05 + 0.1, maximal inhibi- 
tion = 100%; (0) (-)-PN 200-I 10 - ICse = 434 f 140 nM, nn = 0.83 + 0.20, maximal inhibition = 100%; (m) d-cis- 
diltiazem - E&e = 4.5 + 1.7 hM, nn = 1 .O + 0.34, maximal stimulation = 269 + 40%; (0) 1-cis-diltiazem - < 10% in- 
hibition at 10,uM; (A) (-)-desmethoxyverapamil - ECse = 187 i 113 nM, nn = 2.2 + 0.21, maximal stimulation 
= 110 k 16%;.(A) (+)-desmethoxyverapamil - 56010 inhibition at 10 PM. (B) Saturation analysis of equilibrium binding 
in the absence or presence of d-c~-diltiazem. ( +)-[3H]PN 200-110 (0.4-30 nM) was incubated with 0.105 pg channel 
protein for 60 min at 25°C with (0) and without (0) lOOaM d-c~-diltiazem in the incubation mixture. Scatchard 
transformation of the data is shown. The following parameter estimates represent he best fit of the specific binding 
data to a monophasic saturation isotherm: d-cis-diltiazem absent - & = 7.2 rt 1.1 nM, B,,, = 264.7 + 14 pM 
(equivalent to 627 f 33 pmol/mg protein); d-cis-diltiazem present - & = 2.87 f 0.5 nM, B,,, = 630 + 35 pM 
(equivalent to 1500 + 83 pmol/mg protein). 
channel antagonist [la], was inactive. The phenyl- 
alkylamine ( - )-desmethoxyverapamil inhibits 1,4- 
dihydropyridine binding to particulate Ca2+ chan- 
nels (fig.2). ( - )-Desmethoxyverapamil is approx. 
3 orders of magnitude more potent at inhibiting 
the binding of the overt agonist ( +)j3H]Bay K 
8644 than the potent antagonist ( +)-J3H]PN 
200-110. The mechanism of inhibition was 
evaluated for ( +)-r3H]PN 200-110 and is of a 
mixed type (BmaX decrease, & increase). In con- 
trast, ( - )-desmethox~erapamil did not inhibit 
( +)-f3H]PN 200-l 10 binding to purified channels 
but stimulated it. The ECso vaiue was 
187 * 113 nM (n = 3), the maximum stimulation 
206 
being 110 + 16%. Interestingly, the (+) enan- 
tiomer of desmethoxyverapamil was inhibitory for 
both the membrane-bound and purified channel 
(not shown). As reported for the particulate chan- 
nel 141, the 1,4-dihydrop~idines ( + )-PN 200-l 10 
and (- )-PN 200-I 10 exhibited stereospecific om- 
petition. 
3.2. Characteristics of the 
( - ~-~~~desmeth~xy~era~arni~-lamented 
~~enylaiky~ami~e receptors 
The interaction of the high-affinity probe (-)- 
[3H]desmethoxyverapamil with the phenylalkyl- 
amine-selective receptors of the particulate Ca2+ 
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Fig.2, Mechanism of inhibition of (+)-[%]PN 200-l 10 
binding to partially purified skeletal muscle t-tubule 
membranes by (-)-desmethoxyverapamil. ( +)-[3H]PN 
200-110 (0.5-24 nM) was incubated with 7,8 pg mem- 
brane protein for 60 min at 25°C in the absence and 
presence of 100 PM ( - ~-desmethox~er~p~il. Scatch- 
ard transformation of the specific binding data is shown. 
Control (e) - Kd = I.0 _t 0.3 nM, S,,, = 672 rt 5.8 pM 
(equivalent to 21.5 & 0.2 pmol/mg protein); 100 ,uM 
( - )-desmethoxyverapamil present (0) - & = 3.93 + 
0.12 nM, Bmax = 432.7 + 4.7 pM (equivalent to 13.8 + 
0.1 pmol/mg protein). (Inset) Comparison of inhibition 
of (+)-[31-I]PN 200-110 (0) and (+)-[3H]Bay K 8644 
(0) binding to particulate skeletal muscle t-tubule mem- 
branes by (- )-desmethoxyverapamil. 0 4-0.6 nM (+ )- 
(3H]PN 200-110 or 1%3,OnM (+)-[3H]Bay K 8644 
were incubated with 7-10 or 2&3Opg membrane pro- 
tein, respectively. Ligand bound in the presence of in- 
creasing concentrations of f - ~-desmetho~yverapam~ 
(B) was normalized with respect o control binding (Bc). 
Points are means from at least 2-3 experiments, ICSO 
values (* asymptotic SD) for binding inhibition were 
38.9 f 10 nM (76% + 4% maximal inhibition) with 
( +)-[3H]Bay K 8644 and 46 + 11 ,uM (assuming a max- 
imal inhibition of 100010) when ( +)j3H]PN 200-l 10 was 
the ligand. 
. 
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Fig.3. Equilibrium binding properties of the phenylalkylamine-selective receptor, labelled by ( -)-[3H]desmethox- 
yverapamil. (A) Stereospecific regulation of ( -)-[3H]desmethoxyverapamil binding by the enantiomers of PN 200-l 10 
and 202-791. The competitive inhibition by unlabelled ( - )-desmethoxyverapamil s also illustrated. ( - )- 
[%I]Desmethoxyverapamil (6-10 nM) was incubated with 0.3-0.6ag channel protein for 60 min at 25°C. Be and B are 
defined as in fig.1. Points are means from at least 2-3 experiments. 1Cs0 (or ECss) values and apparent Hill slopes (nu) 
are given -t asymptotic SD: (e) (+ )-PN 200- 110 - EC 50 = 7.0 * 1.9 nM, no = 0.95 + 0.23. maximal stimulation 
= 201 it 9%; (0) (-)-PN 200-I 10 - 10% stimulation at 3 PM; (0) (R)-202-791 - E&e = 44 + 8 nM, tiH = 1.4 + 
0.3, maximal stimulation = 151 & 8Yo; (*)(a - 202-791 - EC50 = 1.46 f 0.48pM, nn = 1.5 + 0.6,.58.1% maximal 
inhibition at 10&M; (A) ~-~-d~methoxyverapamil - EC 50 = 99 +- 18 n&l, 8~ = I.01 f O.i7, maximal inhibition lOO?&. 
(B) Mechanism of stimulation of ~-~-[3H]d~methoxyverapamil binding by ( f )-PN 200-l 10. Saturation experiments 
were performed as described in section 2, with and without 1 FM f f )-PN 200-f 10 in the incubation mixture. Scatchard 
transformation of the data of one typical experiment is shown. l3est fits were obtained with the following parameter 
estimates. Control (0): & = 73.7 f 10 nM, B,,, = 490.7 + 42 pM. 1 pM (+)-PN 200-l 10 present (0): & = 26.4 
+ 5.6 nM, B,,, = 682 -f 51 pM. 
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channel in skeletal muscle was evaluated previous- 
ly in detail [15]. Fig.3A shows that (+)-PN 
200-I 10 stimulates ( -)-[3H]desmethoxyverapamil 
binding (EC50 = 7.0 + 1.9 nM) to the purified 
channel whereas it was an allosteric inhibitor for 
particulate preparations [ 151. The average max- 
imum stimulation was 201 rt 9% (n = 3). In satura- 
tion studies the & for ( -)-[3H]desmethox- 
yverapamil was 91 f 17 nM; with 1 PM (+)-PN 
200-l 10 present the Kd decreased to 48 f 11 nM 
(n = 3) (fig.3B), whereas B,, increased by 
64 + 24%. (-)-PN 200-110 was without effect. 
We have also investigated the enantiomers of so- 
called agonistic 1,4_dihydropyridines. As can be 
seen in fig.3 (-)(R)-202-791 stimulated whereas 
( +)(S)-202-791 was inhibitory. The (R) enan- 
tiomer is a potent Ca 2+-channel blocker whereas 
the (5’) enantiomer is a potent agonist [19]. 
Likewise (+)(4R)-Bay K 8644 (a channel blocker) 
stimulated (EC50 = 100 t 58 nM, maximal stimu- 
lation = 33 -t 9%) whereas ( -)(4S)-Bay K 8644, a 
channel agonist 1201, was inhibitory (not shown). 
The benzothiazepine diastereoisomers blocked 
( - )-[3H]desmethox~erapamil binding in a 
stereospecific manner. The IGO value for d-cis- 
diltiazem was 3.8 f 2,uM vs 19.0 f 3 PM for l-cis- 
diltiazem. 
4. DISCUSSION 
In this report we show that 2 of the postulated 
3 drug-receptor sites of the Ca2+ channel can be 
directly identified in purified preparations with a 
post-labelling procedure, namely the 1 ,Cdihydro- 
p~idine-selective and the phenyl~kylamine- 
selective receptor. The presence of a third receptor 
(the benzothiazepine-selective site) is inferred from 
the stimulation of 1 ,bdihydropyridine (e.g. ( + )- 
13H]PN 200-110) binding by the Ca2+-channel 
blocker d-cis-diltiazem, whereas the diastereo- 
isomer I-cis-diltiazem was inactive. The 1,4-di- 
hydropyridine receptor recognized the optically 
pure enantiomers of the benzoxadiazole 1,4-di- 
hydropyridine PN 200-l 10 with a eudismic ratio of 
> 30. This strongly supports our claim that we 
have characterized the 1 ,Cdihydropyridine recep- 
tor of the Ca2+ channel and not an unrelated 1,4- 
dihydropyridine site. Such sites reside, e.g. on the 
nucleoside transporter [21] which has the same 
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molecular mass (50 kDa) as the ~-subunit of the 
Ca2+ channel [7,8]. 
Some features clearly distinguish purified and 
membrane-bound channels. It has been reported 
that membrane-bound and solubilized channels 
have a Kd of 0.7 nM for (+)j3H]PN 200-110 141. 
The affinity for this benzoxadiazole 1 ,Cdihydro- 
pyridine is decreased upon purification by a factor 
of 10, the Kd now amounting to 8.8 nM. Whereas 
with respect o B,,, and Kd there are only small ef- 
fects of d-cis-diltiazem on (+)-[3H]PN 200-110 
binding to the membrane-bound structure [4,17] 
there is a dramatic increase of Bmax in the purified 
preparation, accompanied by a 2-fold increase in 
affinity. Apparently, ( +)-[3H]PN 200-l 10 is not 
able to stabilise all of the 1,Cdihydropyridine 
receptors in the high-affinity state unless d-cis- 
diltiazem (acting through its own site) shifts the 
equilibrium towards the high-affinity state. There 
is compelling evidence that in intact cells this high- 
affinity state corresponds to the inactivated chan- 
nel [22]. In particulate preparations high-affinity 
stabilisation is dependent on temperature and on 
the structure of the 1,4-dihydropyridine. Overt 
agonists (as is (+)-[‘HIBay K 8644) stabilise (in 
contrast to the potent antagonist ( +)-[3H]PN 
200-110) only a minor fraction of channels in the 
high-affinity state [12]. The partial agonists 
[3H]nifedipine, 13H] nimodipine or 13H]nitren- 
dipine are intermediate in behaviour and d-cis- 
diltiazem is required to label maximally the 
1 ,Cdihydropyridine receptors with these ligands. 
Thus, the purified channel has acquired properties 
with respect o (+ )-[3H]PN 200-l 10 binding which 
the membrane-bound structure shows only for par- 
tial or overt agonists. ( - ~-Desmethox~erap~il s 
not a negative allosteric heterotropic inhibitor of 
1,Cdihydropyridine binding as it is for the par- 
ticulate preparation but stimulates (as does d-cis- 
diltiazem). The stimulatory effect of (-)- 
desmethoxyverap~il on ( +)-[3H]PN 200-l 10 
binding does not indicate that this phenyl- 
alky’tamine binds to the benzothiazepine-selective 
receptor. Instead, stimulatory or inhibitory effects 
of a Ca2+ channel drug specific for the 
phenylalkylamine receptor on the kinetic paraeters 
of a ligand binding to the 1,4-dihydropyridine 
receptor are best explained by an allosteric model 
[12,23]. In this model the equilibrium of two states 
(e.g. inactivated and resting) is governed by the 
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allosteric constant in the absence of drug. If the 
labelled ligand binds better to the inactivated state 
the second drug may or may not affect the 
equilibrium by changing the allosteric constant. 
This can result in either an increase or decrease of 
the fraction of channels labelled in the high- 
affinity state. Interesting examples in this context 
are the stimulation of i3H]-nimodipine binding to 
membrane-bound channels by the potent phenyl- 
alkylamine ( - )-D-600 (methoxyverapamil) [ 131 and 
the lOOO-fold higher potency of (-)-desmethoxy- 
verapamil in inhibiting binding of the overt agonist 
(&)j3H)Bay K 8644 compared to the overt an- 
tagonist ( +)-f3H]PN 200-l 10. Clearly, these 
effects can only be rationalized within an allosteric 
model. The question arises as to whether the con- 
formational changes in the two directly labelled 
receptor domains of the purified channel are 
coupled reciprocally as shown by us for the 
membrane-bound structure. We can convincingly 
demonstrate that this is indeed the case. The potent 
Ca’+-channel antagonist ( -I-)-PN 200-l 10 is a 
negative heterotropic allosteric regulator of 
( -)-[3HJdesmethox~erap~il binding to the 
membrane-bound channel. In the case of the 
purified channel it stimulated the binding of the 
phenylalkylamine as the phenylalkylamine 
stimulated ( +)-[‘H]PN 200-l 10 binding. The 
antagonistic enantiomers ( - )(R)-202-791 and 
( + )(4~)-Bay K 8644 were also stimulatory whereas 
the agonistic enantiomers (- )(4S)-Bay K 8644 and 
(+ )(S)-202-791 were inhibitory on (- )-[3H]des- 
methoxyverapamil binding. This finding suggests 
that the high- and low-affinity states of the isolated 
channel are in analogy to the respective inactivated 
and resting open conformations of the channel in 
situ and that the drugs act as agonists and an- 
tagonists by changing the ratio of these states. 
Clearly, the ratio of states (i.e. the allosteric con- 
stant) is changed when the channel is purified. This 
is accompanied by an increase in the dissociation 
constants by one or even two orders of magnitude 
for our labels ( +)-[3H]PN 200-I 10 and ( -)-[3H]- 
desmethoxyverapamil. Others have tried to main- 
tain the Ca2” channel in the high-affinity state 
(with respect o 1 ,Cdihydropyridines) by prelabel- 
ling with 13H]nitrendipine in the presence of d-cis- 
diltiazem [7,8]. However, we have shown by 
radiation-inactivation that d-cis-diltiazem induces 
a drastic decrease in the size of the 1,6dihydro- 
pyridine-sei~tive site, namely by 60 kDa [24,25]. 
It is yet not known whether this indicates the 
dissociation of a subunit or reflects only a change 
in the radiation-sensitive domain. Nevertheless, 
prelabelling in the presence of an allosteric 
regulator may cause the loss of a channel compo- 
nent unless proven otherwise. Alterations of the 
allosteric constant upon purification have impor- 
tant consequences for monitoring the drug recep- 
tors of the Ca2+ channel with the currently avail- 
able labels. From the above considerations radio- 
active ligands with very high affinity for the inac- 
tivated state should be helpful. Alternatively, 
probes which bind to the channel in a voltage-inde- 
pendent manner may be used. The reasons for the 
observed differences between the membrane- 
bound and purified channel have not yet been 
clarified. The loss of an endogenous regulator, 
altered composition of associated lipids, loss or 
dephosphorylation of a subunit (e.g. the P-sub- 
unit) must be considered as possibilities. Finally, 
although we have demonstrated by direct labelling 
that two drug-receptor sites are reciprocally 
allosterically coupled on purified channels, the 
presence (and coupling) of the third (the benzo- 
thiazepine-selective site) has only been indirectly 
proven. The quantitation and characterisation of 
this site require probes of higher affinity than the 
currently available d-cis-f3H]diltiazem. 
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